CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review Select Drug-Drug Interactions With Direct Oral Anticoagulants Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Effect of a Home-Based Wearable Continuous ECG Monitoring Patch on Detection of Undiagnosed Atrial Fibrillation The mSToPS Randomized Clinical Trial Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study Mode of Death in Heart Failure With Preserved Ejection Fraction Generalizing Intensive Blood Pressure Treatment to Adults With Diabetes Mellitus 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with)

Original ResearchVolume 13, Issue 10, May 2020

JOURNAL:JACC: Cardiovascular Interventions Article Link

Evaluation and Management of Nonculprit Lesions in STEMI

T Thim, NW van der Hoeven, C Musto et al. Keywords: CFR; FFR; iFR; nonculprit coronary lesions; STEMI

ABSTRACT

Nonculprit lesions are frequently observed in patients with ST-segment elevation myocardial infarction. Results from recent randomized clinical trials suggest that complete revascularization after ST-segment elevation myocardial infarction improves outcomes. In this state-of-the-art paper, the authors review these trials and consider how best to determine which nonculprit lesions require revascularization and when this should be performed.